<DOC>
	<DOCNO>NCT00005808</DOCNO>
	<brief_summary>Phase I trial study effectiveness photodynamic therapy lutetium texaphyrin treat patient cervical intraepithelial neoplasia . Photodynamic therapy use light drug lutetium texaphyrin make abnormal cell sensitive light may kill abnormal cell cervix prevent development cervical cancer</brief_summary>
	<brief_title>Photodynamic Therapy Using Lutetium Texaphyrin Treating Patients With Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine optimal dosage least toxicity lutetium texaphyrin well length time follow systemic injection provide maximum differential drug uptake target dysplastic squamous cell normal squamous epithelium give patient cervical intraepithelial neoplasia ( CIN ) . II . Determine , histomorphometry , photodynamic light dose demonstrate great treatment selectivity normal cervical epithelium CIN least amount cervical pain necrosis . OUTLINE : This dose-escalation study lutetium texaphyrin ( part 1 ) follow dose-escalation study light fluence ( part 2 ) . Part 1 : Patients receive lutetium texaphyrin IV 5-20 minute . Patients undergo vivo tissue assessment spectrometer 0 , 1 , 3 , 5 , 12 , 24 hour loop electrical excision procedure ( LEEP ) 24 hour lutetium texaphyrin infusion . Part 2 : Patients receive lutetium texaphyrin IV 5-20 minute . A laser deliver 730 nm light cervix 4 , 8 , 16 minute . Patients undergo LEEP 4 , 8 , 12 hour exposure cervix light source . Cohorts 9 patient receive escalate dos lutetium texaphyrin ( part 1 ) light fluence ( part 2 ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 9 patient experience dose-limiting toxicity . Patients follow 48 hour , weekly 1 month , 4 month . PROJECTED ACCRUAL : A maximum 54 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Motexafin lutetium</mesh_term>
	<criteria>Cervical intraepithelial neoplasia ( CIN ) grade II III No cytologic , colposcopic , histologic evidence invasive squamous cell carcinoma No evidence glandular atypia Pap smear , endocervical curettage , biopsy No inadequate colposcopy ( i.e. , entire transformation zone visualize and/or upper limit colposcopically abnormal lesion visualize fully ) HIV positive currently antiviral therapy Performance status 02 WBC great 4,000/mm^3 Absolute neutrophil count great 2,000/mm^3 Platelet count normal Liver enzymes normal No liver impairment BUN normal Creatinine normal No renal insufficiency No coronary artery disease No cardiac arrhythmia No congestive heart failure Not pregnant nursing Fertile patient must use effective contraception least 1 month study No serious medical illness ( e.g. , noninsulin insulindependent diabetes connective tissue disorder ) No prior concurrent malignancy No know G6PD deficiency No porphyria No history 2 prior ablative/excisional therapy ( i.e. , cryotherapy , laser ablation , loop electrical excision procedure , cold knife cone biopsy ) No concurrent nonsteroidal antiinflammatory drug ( NSAIDS ) No concurrent significant medication/therapy : Antihypertensives , antiarrhythmic , inotropic agent cardiopulmonary disease Diuretics renal insufficiency Steroids NSAIDs connective tissue disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>